Doravirine/lamivudine/tenofovir disoproxil

Merck Announces New Analyses Showing Additional Safety and Efficacy Data for Investigational Islatravir in Combination with Doravirine in Adults with HIV-1 Infection

Retrieved on: 
Monday, July 6, 2020
Research, Infectious diseases, Clinical trials, Biotechnology, AIDS, Health, Pharmaceutical, General Health, Science, Medical specialties, Medicine, Health, RTT, Clinical research, Doravirine/lamivudine/tenofovir disoproxil, Adverse event, Bronchitis, Syphilis, Diarrhea, Islatravir (MK-8591), Merck

These findings add to the growing body of evidence supporting the potential of islatravir and doravirine for the treatment of people living with HIV.

Key Points: 
  • These findings add to the growing body of evidence supporting the potential of islatravir and doravirine for the treatment of people living with HIV.
  • Through Week 48, a lower rate of drug-related adverse events (AE) occurred in the islatravir groups (7.8%) compared with the DELSTRIGO group (19.4%).
  • The most common reported adverse events (reported by >10% participants) in the DELSTRIGO-treated group were diarrhea (16.1%), bronchitis (12.9%) and syphilis (12.9%).
  • The safety of DELSTRIGO in virologically-suppressed adults was based on Week 48 data from subjects in the DRIVE-SHIFT trial.

Merck’s PIFELTRO™ (doravirine) and DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive US FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed

Retrieved on: 
Friday, September 20, 2019
AIDS, FDA, Health, Clinical trials, Pharmaceutical, Drugs, Organic compounds, Hepatotoxins, Chemical compounds, RTT, Combination drugs, Nitriles, Gilead Sciences, Fixed-dose combination, Doravirine/lamivudine/tenofovir disoproxil, Reverse-transcriptase inhibitor, Tenofovir disoproxil

PIFELTRO (doravirine, 100 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral agents.

Key Points: 
  • PIFELTRO (doravirine, 100 mg) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral agents.
  • DELSTRIGO is a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg).
  • In addition, 91% of participants who switched to DELSTRIGO on Day 1 (ISG) had HIV-1 RNA
  • Overall, the safety profile in virologically suppressed adult participants was similar to that in participants with no antiretroviral treatment history.